## Answer
(model generated chain of thought explanation)

Given the patient's history of diabetes, hypertension, hyperlipidemia, and obesity, as well as his recent myocardial infarction with a bare metal stent, we need to consider medications that are not only effective against ventricular tachycardia but also have favorable pharmacokinetic profiles.

Firstly, let's evaluate the options:

A. Quinidine - While quinidine is an anti-arrhythmic agent, it has a broad spectrum of activity and can be pro-arrhythmic in some patients, particularly those with heart failure or significant coronary artery disease. Its use is also limited by its narrow therapeutic index.

B. Lidocaine - This local anesthetic has been used for decades as an anti-arrhythmic agent due to its efficacy against ventricular tachycardia and its favorable pharmacokinetic profile, including a long half-life that allows for once-daily dosing. It is also relatively safe in patients with heart failure.

C. Dofetilide - This medication has a unique mechanism of action as a potassium channel blocker, which can be beneficial in certain arrhythmias like atrial fibrillation. However, its use is limited by its narrow therapeutic index and potential for pro-arrhythmic effects in some patients.

D. Flecainide - This anti-arrhythmic agent has been used for many years but is less commonly used today due to concerns about its association with cardiac arrhythmias, particularly ventricular tachycardia. Its pharmacokinetics are not as favorable as lidocaine's, and it may require more frequent dosing.

Considering the patient's history of diabetes, hypertension, hyperlipidemia, and obesity, which can increase the risk of arrhythmias due to electrolyte imbalances and cardiac remodeling, we should opt for an anti-arrhythmic agent with a high selectivity for ischemic cardiac myocytes. Lidocaine (B) is the best choice among these options due to its favorable pharmacokinetics, efficacy against ventricular tachycardia, and relatively safe profile in patients with heart failure.

## Answer Explanation
The key factors that guided our decision are:

1. **Ischemic cardiac myocytes selectivity**: We want an anti-arrhythmic agent that is selective for the myocardium, reducing the risk of arrhythmias in non-ischemic tissues.
2. **